公开(公告)号：US5869525A

公开(公告)日：1999-02-09

申请号：US647767

申请日：1996-05-15

申请人： Shinobu Ito ,  Eiji Ogata ,  Nobuhiko Miwa

发明人： Shinobu Ito ,  Eiji Ogata ,  Nobuhiko Miwa

IPC分类号： A61K31/375 ,  A61K31/34 ,  A61K31/70 ,  A61K31/715

CPC分类号： A61K31/375

摘要： An L-ascorbic acid drug for intracerebral administration comprising one or more stable activity L-ascorbic acid compounds and one or more blood brainbarrier deobstruents. Also disclosed is a method for increasing intracerebral concentration of L-ascorbic acid in a human being comprising administering by injection an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds. Additionally disclosed is a method for increasing intracerebral concentration of L-ascorbic acid in a human being comprising administering by injection an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds and one or more blood brainbarrier deobstruents. Also disclosed is a method for treating diseases or disorders that result from intracerebral bloodstream inhibition or intracerebral bloodstream lowering comprising administering by injection to a person in need of such treatment, a dosage effective amount of an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds. Additionally disclosed is a method for treating diseases or disorders that result from intracerebral bloodstream inhibition or intracerebral bloodstream lowering comprising administering by injection to a person in need of such treatment, a dosage effective amount of an L-ascorbic acid drug comprising one or more stable activity L-ascorbic acid compounds and one or more blood brainbarrier deobstruents.

摘要翻译： 一种用于脑内给药的L-抗坏血酸药物，其包含一种或多种稳定的活性L-抗坏血酸化合物和一种或多种血液脑阻滞剂。 还公开了增加人体中L-抗坏血酸的脑内浓度的方法，包括通过注射施用包含一种或多种稳定活性L-抗坏血酸化合物的L-抗坏血酸药物。 另外公开了一种增加人抗坏血酸的脑内浓度的方法，包括通过注射施用包含一种或多种稳定的活性L-抗坏血酸化合物和一种或多种血脑屏障去除剂的L-抗坏血酸药物。 还公开了一种用于治疗由脑内血流抑制或脑内血流降低引起的疾病或病症的方法，其包括通过注射给予需要这种治疗的人，剂量有效量的包含一种或多种稳定活性的L-抗坏血酸药物 L-抗坏血酸化合物。 另外公开了一种治疗由脑内血流抑制或脑内血流降低引起的疾病或病症的方法，其包括通过注射给予需要这种治疗的人，剂量有效量的包含一种或多种稳定活性的L-抗坏血酸药物 L-抗坏血酸化合物和一种或多种血脑屏障阻断剂。

公开(公告)号：US20080206222A1

公开(公告)日：2008-08-28

申请号：US11792520

申请日：2005-08-05

申请人： Nobuhiko Miwa ,  Shinobu Ito ,  Kenji Matsubayashi

发明人： Nobuhiko Miwa ,  Shinobu Ito ,  Kenji Matsubayashi

IPC分类号： A61K47/02 ,  A61K47/06 ,  A61K31/04 ,  A61K31/66 ,  A61K31/195 ,  A61K31/675 ,  A61K31/10 ,  A61K31/505 ,  A61K31/045 ,  A61K31/522 ,  A61K31/70 ,  A61K31/4985 ,  A61K31/44 ,  A61K31/535 ,  A61K31/40 ,  A61K31/35 ,  A61K38/16 ,  A61K38/02 ,  A61K31/56 ,  A61K31/135 ,  A61K31/00 ,  A61K38/46 ,  A61K33/24 ,  A61K31/716 ,  A61K31/727 ,  A61K36/18 ,  A61P35/00

CPC分类号： A61Q9/00 ,  A61K8/19 ,  A61K8/738 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/06 ,  A61K9/145 ,  A61K9/2027 ,  A61K9/2866 ,  A61K31/01 ,  A61K31/02 ,  A61K31/045 ,  A61K31/395 ,  A61K33/44 ,  A61K45/06 ,  A61K47/10 ,  A61K47/14 ,  A61K47/32 ,  A61K47/34 ,  A61K47/44 ,  A61K47/6951 ,  A61K2800/56 ,  B82Y5/00 ,  A61K2300/00

摘要： A preventive/therapeutic composition for free radical diseases, characterized by containing as an active ingredient at least one kind of a fullerene, a fullerene derivative, and a composite comprising a fullerene or fullerene derivative and an organic compound with which the fullerene or derivative has been modified or clathrated. The composition is reduced in side effects, has the high ability to eliminate free radicals in the body, and further has excellent preparation stability.

摘要翻译： 一种自由基疾病的预防/治疗组合物，其特征在于，含有作为活性成分的至少一种富勒烯，富勒烯衍生物和包含富勒烯或富勒烯衍生物和富勒烯或衍生物的有机化合物的复合物 修改或包扎。 组合物的副作用降低，具有消除体内自由基的高能力，进一步具有良好的制剂稳定性。

公开(公告)号：US5162304A

公开(公告)日：1992-11-10

申请号：US686975

申请日：1991-04-18

申请人： Shingo Nakamura ,  Yoshichika Nishimura ,  Nobuhiko Miwa

发明人： Shingo Nakamura ,  Yoshichika Nishimura ,  Nobuhiko Miwa

IPC分类号： A61K31/045

CPC分类号： A61K31/045

摘要： A pharmaceutical composition comprising, in admixture with a pharmacologically acceptable carrier, an isomonool of the formula ##STR1## wherein R is an alkyl group with 1 to 5 carbon atoms, and n is an integer of 4 to 22, have carcinostatic, carcinostasis-reinforcing and carcinogenesis-preventing activity.

公开(公告)号：US20100112086A1

公开(公告)日：2010-05-06

申请号：US12529895

申请日：2008-07-03

申请人： Nobuhiko Miwa ,  Hiroshi Tamura ,  Keisou Iwai ,  Osamu Mishima ,  Suehiro Sakai ,  Katsunori Yuuki ,  Masanori Akioka

发明人： Nobuhiko Miwa ,  Hiroshi Tamura ,  Keisou Iwai ,  Osamu Mishima ,  Suehiro Sakai ,  Katsunori Yuuki ,  Masanori Akioka

IPC分类号： A61K33/00 ,  C01B5/00 ,  C02F1/461 ,  A61P43/00 ,  A61Q19/00

CPC分类号： A61K8/19 ,  A61K2800/83 ,  A61Q19/10 ,  C02F1/4618 ,  C02F2001/4619 ,  C02F2001/46195 ,  C02F2103/026 ,  C02F2201/46115 ,  C02F2209/04 ,  C02F2209/06 ,  C02F2209/30

摘要： An electrolytically reduced water which consists of an alkali ion water prepared by ion exchange and has a dissolved hydrogen concentration of 0.20 ppm or above, an oxidation-reduction potential of −150 mV to −500 mV, and a hydrogen ion component of pH6.5-10.5 and which is quantitatively specified in the reducing power capable of inhibiting the oxidative deterioration of fat in the cutis through the elimination of active oxygen due to the characteristics of hydrogen, the oxidation-reduction potential characteristics of high reducing action, and alkaline characteristics and can activate the skin to inhibit the oxidative deterioration and suppress lumpy fat (cellulite).

摘要翻译： 一种电解还原水，其由通过离子交换制备的碱性离子水组成，溶解氢浓度为0.20ppm以上，氧化还原电位为-150mV至-500mV，氢离子成分为pH6.5 -10.5，其能够通过由于氢的特性消除活性氧，还原作用高的氧化还原电位特性和碱性特性，能够抑制角质形成体中的脂肪的氧化劣化的还原能量定量地表示， 可以激活皮肤抑制氧化恶化，抑制块状脂肪（脂肪）。

公开(公告)号：US5190978A

公开(公告)日：1993-03-02

申请号：US589580

申请日：1990-09-28

申请人： Shingo Nakamura ,  Yoshichika Nishimura ,  Sensuke Naruse ,  Nobuhiko Miwa

发明人： Shingo Nakamura ,  Yoshichika Nishimura ,  Sensuke Naruse ,  Nobuhiko Miwa

IPC分类号： A61K31/045

CPC分类号： A61K31/045

摘要： Presented are pharmaceutical carcinostatic compositions comprising as active ingredient a diol represented by the formula: ##STR1## wherein n is an integer of 6 to 33; or by the formula: ##STR2## wherein R is hydrogen or C.sub.1 to C.sub.5 alkyl and m is an integer of 3 to 21; and methods of treatment of cancer of animals with a diol represented by the above formulas. The compositions and the methods are useful for cancer treatment without causing side effects.

摘要翻译： 本发明提供了药物制剂组合物，其包含由下式表示的二醇作为活性成分：其中n为6至33的整数; 或通过下式：其中R是氢或C1-C5烷基，m是3-21的整数; 以及用上述式表示的二醇处理动物癌症的方法。 组合物和方法可用于癌症治疗而不引起副作用。